Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a
leading producer of critical reagents for the discovery,
development, and commercialization of novel therapies, vaccines,
and molecular diagnostics, today announced financial results for
the third quarter ended September 30, 2023.
“Today we reported a solid third quarter, both
financially and operationally, against a difficult market
backdrop,” said Stephen Gunstream, President and Chief Executive
Officer of Teknova. “We have expanded the use of our new
state-of-the-art GMP facility to produce a variety of products,
such as single-use bags and bottles, to meet the needs of customers
in our target markets. While we continue to see emerging biotech
customers conserving capital, we remain enthusiastic about our
position in the market and the long-term potential of our
business.”
“We are very pleased to have completed an equity
capital raise of $22.9 million in September, which along with
repayment of $10.0 million of debt strengthens our balance sheet.
Through the third quarter of 2023, we have also managed our overall
expenses and capital expenditures to plan and now expect full-year
free cash outflow to be less than $30 million,” explained Matt
Lowell, Teknova’s Chief Financial Officer.
Corporate Updates
- Raised $22.9 million of equity capital through a registered
direct offering and concurrent private placement, and paid down
$10.0 million of long-term debt
- Validated manufacturing processes and automation equipment in
new GMP facility to be able to service nearly all bioprocessing
customer needs, including standard-use bottles and 1 L to 200 L
single-use bags
- Launched an additional version of our first-of-its-kind AEX
Buffer Screening Kit for the AAV6 serotype as part of our
proprietary product line, AAV-Tek Solutions, along with more than
60 off-the-shelf reagents to help expedite plasmid production
across the entire workflow
Revenue for the Third Quarter and
Year-to-Date
|
For the Three Months Ended September 30, |
|
For the Nine Months Ended September 30, |
(Dollars in
thousands) |
2023 |
|
2022 |
|
2023 |
|
2022 |
Lab Essentials |
$ |
7,274 |
|
$ |
9,470 |
|
$ |
22,112 |
|
$ |
24,838 |
Clinical Solutions |
|
597 |
|
|
919 |
|
|
5,859 |
|
|
7,673 |
Other |
|
298 |
|
|
303 |
|
|
846 |
|
|
1,018 |
Total revenue |
$ |
8,169 |
|
$ |
10,692 |
|
$ |
28,817 |
|
$ |
33,529 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third Quarter 2023 Financial
Results
Total revenue for the third quarter 2023 was $8.2
million, down 24% compared to $10.7 million in the third quarter
2022. Lab Essentials revenue was $7.3 million in the third quarter
2023, down 23% compared to $9.5 million in the third quarter 2022.
Clinical Solutions revenue was $0.6 million, down 35% compared to
$0.9 million in the third quarter 2022.
Gross profit for the third quarter 2023 was $1.5
million, compared to $4.8 million in the third quarter 2022. Gross
margin for the third quarter 2023 was 18.0%, compared to 44.6% in
the third quarter 2022. The decrease in gross profit percentage was
driven primarily by the decrease in revenue and the associated
lower absorption of fixed manufacturing costs, and to a lesser
extent by increased overhead costs, which were partially offset by
reduced headcount.
Operating expenses for the third quarter 2023 were
$10.2 million, compared to $27.7 million in the third quarter 2022.
Excluding the non-recurring, non-cash charges of $0.4 million in
the third quarter 2023 related to the write-off of ATM Facility
offering costs and the $16.6 million goodwill impairment charge
recorded in the third quarter 2022, operating expenses were down
$1.3 million in the third quarter 2023 compared to the third
quarter 2022. The decrease was driven primarily by reduced
headcount and spending, in particular in professional fees.
Net loss for the third quarter 2023 was $10.2
million, or negative $0.34 per diluted share, compared to $22.5
million, or negative $0.80 per diluted share, for the third quarter
2022.
Adjusted EBITDA for the third quarter 2023 was
negative $5.5 million, compared to negative $4.6 million for the
third quarter 2022. Free Cash Flow was negative $5.4 million for
the third quarter 2023, compared to negative $14.9 million for the
third quarter 2022.
2023 Outlook
Teknova now anticipates that revenue will be at the
low end of its $37 million to $40 million guidance range for the
fiscal year ending December 31, 2023 (“2023”). The Company now
anticipates free cash outflow to be less than its previously
communicated target of $30 million for 2023.
Upcoming Investor Conference
Presentations
Stephens Annual Investment ConferenceWednesday,
November 15th, 2023 at 4:00 p.m. ET
35th Annual Piper Sandler Healthcare
ConferenceWednesday, November 29th, 2023 at 8:30 a.m. ET
Conference Call and Webcast
Teknova will host a webcast and conference call on
Thursday, November 9, 2023, beginning at 5:30 p.m. ET. Participants
can access the live webcast on the Investor Relations section of
the Teknova website and at this link:
https://edge.media-server.com/mmc/p/nsccw7hr. To receive a PIN for
dialing in, participants can register for the webcast via this
link:
https://register.vevent.com/register/BI43a2f4610cbe41f5b78f7d61007caf37.
The webcast will be available for replay on the Company’s website
approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996,
Teknova has been innovating the manufacture of critical reagents
for the life sciences industry to accelerate the discovery and
development of novel therapies that will help people live longer,
healthier lives. We offer fully customizable solutions for every
stage of the workflow, supporting industry leaders in cell and gene
therapy, molecular diagnostics, and synthetic biology. Our fast
turnaround of high-quality agar plates, microbial culture media,
buffers, reagents, and water helps our customers scale seamlessly
from RUO to GMP. Headquartered in Hollister, California, with over
200,000 square feet of state-of-the-art facilities, Teknova’s
modular manufacturing platform was designed by our team of
scientists, engineers, and quality control experts to efficiently
produce the foundational ingredients for the discovery and
commercialization of novel therapies.
Non-GAAP Financial Measures
This press release contains financial measures that
have not been calculated in accordance with U.S. generally accepted
accounting principles (GAAP). Teknova uses the following non-GAAP
financial measures in assessing the performance of its business and
the effectiveness of its business strategies: (a) Adjusted EBITDA
and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss
adjusted for interest income (expense), net, provision for (benefit
from) income taxes, depreciation expense, amortization of
intangible assets, and stock-based compensation expense. Adjusted
EBITDA reflects further adjustments to eliminate the impact of
certain items, including certain non-cash and other items that
Teknova does not consider representative of its ongoing operating
performance.
Teknova defines Free Cash Flow as cash used in
operating activities less purchases of property, plant, and
equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow
in this press release because Teknova believes that analysts,
investors, and other interested parties frequently use these
measures to evaluate companies in Teknova’s industry and that such
measures facilitate comparisons on a consistent basis across
reporting periods. Teknova also believes such measures are helpful
in highlighting trends in Teknova’s operating results because they
exclude items that are not indicative of Teknova’s core operating
performance. Investors should consider non-GAAP financial measures
in addition to, and not as a substitute for, or as superior to,
measures of financial performance prepared in accordance with GAAP.
The non-GAAP financial measures presented by Teknova may be
different from the non-GAAP financial measures used by other
companies.
A full reconciliation of these non-GAAP measures to
the most comparable GAAP measures is included at the end of this
release.
Forward-Looking Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements relating to Teknova’s anticipated total
revenue, including our expectations for 2023 revenue and free cash
outflow guidance, expected growth in Lab Essentials and Clinical
Solutions, ongoing capacity expansion, new research and development
products, prospects, including to achieve profitability, strategy
of managing operating expenses, and long-term growth strategy. The
words, without limitation, “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these or similar identifying words. These
forward-looking statements are based on management’s current
expectations and beliefs and are subject to uncertainties and
factors, all of which are difficult to predict and many of which
are beyond Teknova’s control and could cause actual results to
differ materially and adversely from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, demand for Teknova’s products (including
the potential delay or pausing of customer orders); Teknova’s
assessment of fundamental indicators of future demand across its
target customer base; Teknova’s ability to expand its production,
commercial, and research and development capabilities; Teknova’s
cash flows and revenue growth rate; Teknova’s supply chain,
sourcing, manufacturing, and warehousing; inventory management;
risks related to global economic and marketplace uncertainties,
including those related to the lingering impacts of the COVID-19
pandemic and the conflicts in Ukraine and the Middle East; reliance
on a limited number of customers for a high percentage of Teknova’s
revenue; potential acquisitions and integration of other companies;
and other factors discussed in the “Risk Factors” section of
Teknova’s most recent periodic reports filed with the Securities
and Exchange Commission (“SEC”), including in Teknova’s Annual
Report on Form 10-K for the year ended December 31, 2022, and
subsequent Quarterly Reports on Form 10-Q filed with the SEC, all
of which you may obtain for free on the SEC’s website at
www.sec.gov. Although Teknova believes that the expectations
reflected in its forward-looking statements are reasonable, Teknova
does not know whether its expectations will prove correct. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, even if
subsequently made available by Teknova on its website or otherwise.
Teknova does not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable securities laws.
ALPHA TEKNOVA,
INC.Condensed Statements of
Operations(Unaudited)(In
thousands, except share and per share data)
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Revenue |
$ |
8,169 |
|
|
$ |
10,692 |
|
|
$ |
28,817 |
|
|
$ |
33,529 |
|
Cost of sales |
|
6,697 |
|
|
|
5,922 |
|
|
|
19,856 |
|
|
|
18,163 |
|
Gross profit |
|
1,472 |
|
|
|
4,770 |
|
|
|
8,961 |
|
|
|
15,366 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
1,397 |
|
|
|
1,925 |
|
|
|
4,256 |
|
|
|
5,867 |
|
Sales and marketing |
|
2,412 |
|
|
|
2,397 |
|
|
|
6,929 |
|
|
|
6,592 |
|
General and administrative |
|
6,138 |
|
|
|
6,502 |
|
|
|
19,426 |
|
|
|
20,856 |
|
Amortization of intangible assets |
|
287 |
|
|
|
287 |
|
|
|
860 |
|
|
|
861 |
|
Long-lived assets impairment |
|
— |
|
|
|
— |
|
|
|
2,195 |
|
|
|
— |
|
Goodwill impairment |
|
— |
|
|
|
16,613 |
|
|
|
— |
|
|
|
16,613 |
|
Total operating expenses |
|
10,234 |
|
|
|
27,724 |
|
|
|
33,666 |
|
|
|
50,789 |
|
Loss from operations |
|
(8,762 |
) |
|
|
(22,954 |
) |
|
|
(24,705 |
) |
|
|
(35,423 |
) |
Other (expenses) income, net |
|
|
|
|
|
|
|
|
|
|
|
Interest (expense) income, net |
|
(791 |
) |
|
|
70 |
|
|
|
(1,006 |
) |
|
|
85 |
|
Loss on extinguishment of debt |
|
(824 |
) |
|
|
— |
|
|
|
(824 |
) |
|
|
— |
|
Other income, net |
|
233 |
|
|
|
36 |
|
|
|
417 |
|
|
|
36 |
|
Total other (expenses) income, net |
|
(1,382 |
) |
|
|
106 |
|
|
|
(1,413 |
) |
|
|
121 |
|
Loss before income taxes |
|
(10,144 |
) |
|
|
(22,848 |
) |
|
|
(26,118 |
) |
|
|
(35,302 |
) |
Provision for (benefit from) income taxes |
|
9 |
|
|
|
(374 |
) |
|
|
6 |
|
|
|
(1,128 |
) |
Net loss |
$ |
(10,153 |
) |
|
$ |
(22,474 |
) |
|
$ |
(26,124 |
) |
|
$ |
(34,174 |
) |
Net loss per share—basic and
diluted |
$ |
(0.34 |
) |
|
$ |
(0.80 |
) |
|
$ |
(0.91 |
) |
|
$ |
(1.22 |
) |
Weighted average shares used in
computing net loss per share—basic and diluted |
|
29,956,930 |
|
|
|
28,090,267 |
|
|
|
28,810,068 |
|
|
|
28,059,897 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA,
INC.Condensed Balance
Sheets(Unaudited)(In
thousands)
|
|
|
|
|
|
|
As of September 30, |
|
|
As of December 31, |
|
|
2023 |
|
|
2022 |
|
ASSETS |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
$ |
32,079 |
|
|
$ |
42,236 |
|
Accounts receivable, net |
|
5,160 |
|
|
|
4,261 |
|
Inventories, net |
|
11,468 |
|
|
|
12,247 |
|
Income taxes receivable |
|
— |
|
|
|
22 |
|
Prepaid expenses and other current assets |
|
2,371 |
|
|
|
2,374 |
|
Total current assets |
|
51,078 |
|
|
|
61,140 |
|
Property, plant, and equipment,
net |
|
51,579 |
|
|
|
51,577 |
|
Operating right-of-use lease
assets |
|
17,080 |
|
|
|
19,736 |
|
Intangible assets, net |
|
16,696 |
|
|
|
17,556 |
|
Other non-current assets |
|
1,952 |
|
|
|
2,252 |
|
Total assets |
$ |
138,385 |
|
|
$ |
152,261 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
$ |
1,422 |
|
|
$ |
2,449 |
|
Accrued liabilities |
|
5,147 |
|
|
|
6,203 |
|
Current portion of operating lease liabilities |
|
1,770 |
|
|
|
2,223 |
|
Total current liabilities |
|
8,339 |
|
|
|
10,875 |
|
Deferred tax liabilities |
|
1,228 |
|
|
|
1,223 |
|
Other accrued liabilities |
|
125 |
|
|
|
191 |
|
Long-term debt, net |
|
13,168 |
|
|
|
21,976 |
|
Long-term operating lease
liabilities |
|
15,873 |
|
|
|
18,111 |
|
Total liabilities |
|
38,733 |
|
|
|
52,376 |
|
Stockholders’ equity: |
|
|
|
|
|
Preferred stock |
|
— |
|
|
|
— |
|
Common stock |
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
180,782 |
|
|
|
154,891 |
|
Accumulated deficit |
|
(81,130 |
) |
|
|
(55,006 |
) |
Total stockholders’ equity |
|
99,652 |
|
|
|
99,885 |
|
Total liabilities and stockholders’ equity |
$ |
138,385 |
|
|
$ |
152,261 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA,
INC.Condensed Statements of Cash Flows
(Unaudited)(In thousands)
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Operating
activities: |
|
|
|
|
|
|
|
|
|
|
|
Net loss |
$ |
(10,153 |
) |
|
$ |
(22,474 |
) |
|
$ |
(26,124 |
) |
|
$ |
(34,174 |
) |
Adjustments to reconcile net loss
to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Bad debt expense |
|
13 |
|
|
|
2 |
|
|
|
21 |
|
|
|
34 |
|
Inventory reserve |
|
97 |
|
|
|
186 |
|
|
|
130 |
|
|
|
178 |
|
Depreciation and amortization |
|
1,622 |
|
|
|
729 |
|
|
|
4,049 |
|
|
|
2,272 |
|
Stock-based compensation |
|
1,035 |
|
|
|
968 |
|
|
|
3,115 |
|
|
|
2,689 |
|
Deferred taxes |
|
9 |
|
|
|
(374 |
) |
|
|
5 |
|
|
|
(1,125 |
) |
Amortization of debt financing costs |
|
205 |
|
|
|
60 |
|
|
|
415 |
|
|
|
159 |
|
Non-cash lease expense |
|
55 |
|
|
|
75 |
|
|
|
86 |
|
|
|
256 |
|
Loss on disposal of property, plant, and equipment |
|
5 |
|
|
|
210 |
|
|
|
5 |
|
|
|
210 |
|
Long-lived assets impairment |
|
— |
|
|
|
— |
|
|
|
2,195 |
|
|
|
— |
|
Goodwill impairment |
|
— |
|
|
|
16,613 |
|
|
|
— |
|
|
|
16,613 |
|
Loss on extinguishment of debt |
|
824 |
|
|
|
— |
|
|
|
824 |
|
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
(402 |
) |
|
|
227 |
|
|
|
(721 |
) |
|
|
(949 |
) |
Contract assets |
|
1,050 |
|
|
|
(667 |
) |
|
|
— |
|
|
|
(667 |
) |
Inventories |
|
453 |
|
|
|
(2,600 |
) |
|
|
649 |
|
|
|
(5,107 |
) |
Income taxes receivable |
|
22 |
|
|
|
(3 |
) |
|
|
22 |
|
|
|
1,068 |
|
Prepaid expenses and other current assets |
|
(1,736 |
) |
|
|
(1,820 |
) |
|
|
(694 |
) |
|
|
(1,083 |
) |
Other non-current assets |
|
78 |
|
|
|
(407 |
) |
|
|
300 |
|
|
|
(996 |
) |
Accounts payable |
|
414 |
|
|
|
1,247 |
|
|
|
(948 |
) |
|
|
969 |
|
Accrued liabilities |
|
2,049 |
|
|
|
(283 |
) |
|
|
815 |
|
|
|
343 |
|
Other |
|
(22 |
) |
|
|
(21 |
) |
|
|
(66 |
) |
|
|
(61 |
) |
Cash used in operating activities |
|
(4,382 |
) |
|
|
(8,332 |
) |
|
|
(15,922 |
) |
|
|
(19,371 |
) |
Investing
activities: |
|
|
|
|
|
|
|
|
|
|
|
Purchase of property, plant, and
equipment |
|
(972 |
) |
|
|
(6,582 |
) |
|
|
(7,622 |
) |
|
|
(23,419 |
) |
Cash used in investing activities |
|
(972 |
) |
|
|
(6,582 |
) |
|
|
(7,622 |
) |
|
|
(23,419 |
) |
Financing
activities: |
|
|
|
|
|
|
|
|
|
|
|
Proceeds from equity
financing |
|
22,915 |
|
|
|
— |
|
|
|
22,915 |
|
|
|
— |
|
Repayment of long-term debt |
|
(10,000 |
) |
|
|
— |
|
|
|
(10,000 |
) |
|
|
— |
|
Proceeds from financed insurance
premiums |
|
1,004 |
|
|
|
— |
|
|
|
1,004 |
|
|
|
— |
|
Repayment of financed insurance
premiums |
|
(294 |
) |
|
|
— |
|
|
|
(294 |
) |
|
|
— |
|
Proceeds from long-term debt |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5,135 |
|
Payment of debt issuance
costs |
|
— |
|
|
|
— |
|
|
|
(24 |
) |
|
|
(151 |
) |
Payment of exit fee costs |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(135 |
) |
Payment of ATM Facility
costs |
|
— |
|
|
|
— |
|
|
|
(395 |
) |
|
|
— |
|
Proceeds from exercise of stock
options |
|
— |
|
|
|
35 |
|
|
|
76 |
|
|
|
134 |
|
Proceeds from issuance of common
stock under employee stock purchase plan |
|
— |
|
|
|
— |
|
|
|
138 |
|
|
|
144 |
|
Cash provided by financing activities |
|
13,625 |
|
|
|
35 |
|
|
|
13,420 |
|
|
|
5,127 |
|
Change in cash, cash equivalents,
and restricted cash |
|
8,271 |
|
|
|
(14,879 |
) |
|
|
(10,124 |
) |
|
|
(37,663 |
) |
Cash, cash equivalents, and
restricted cash at beginning of period |
|
23,841 |
|
|
|
64,734 |
|
|
|
42,236 |
|
|
|
87,518 |
|
Cash, cash equivalents, and
restricted cash at end of period |
$ |
32,112 |
|
|
$ |
49,855 |
|
|
$ |
32,112 |
|
|
$ |
49,855 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA,
INC.Reconciliation of Non-GAAP Measures to the
Most Comparable GAAP
Measures(Unaudited)(In
thousands)
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Net loss – as reported |
$ |
(10,153 |
) |
|
$ |
(22,474 |
) |
|
$ |
(26,124 |
) |
|
$ |
(34,174 |
) |
Add back: |
|
|
|
|
|
|
|
|
|
|
|
Interest (expense) income, net |
|
(791 |
) |
|
|
70 |
|
|
|
(1,006 |
) |
|
|
85 |
|
Provision for (benefit from) income taxes |
|
9 |
|
|
|
(374 |
) |
|
|
6 |
|
|
|
(1,128 |
) |
Depreciation expense |
|
1,335 |
|
|
|
442 |
|
|
|
3,189 |
|
|
|
1,411 |
|
Amortization of intangible assets |
|
287 |
|
|
|
287 |
|
|
|
860 |
|
|
|
861 |
|
EBITDA |
$ |
(7,731 |
) |
|
$ |
(22,189 |
) |
|
$ |
(21,063 |
) |
|
$ |
(33,115 |
) |
Other and non-recurring
expenses: |
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
1,035 |
|
|
|
968 |
|
|
|
3,115 |
|
|
|
2,689 |
|
Severance pay and other termination benefits |
|
— |
|
|
|
— |
|
|
|
725 |
|
|
|
— |
|
Long-lived assets impairment |
|
— |
|
|
|
— |
|
|
|
2,195 |
|
|
|
— |
|
Goodwill impairment |
|
— |
|
|
|
16,613 |
|
|
|
— |
|
|
|
16,613 |
|
Loss on extinguishment of debt |
|
824 |
|
|
|
— |
|
|
|
824 |
|
|
|
— |
|
Write-off of ATM Facility costs |
|
395 |
|
|
|
— |
|
|
|
395 |
|
|
|
— |
|
Adjusted
EBITDA |
$ |
(5,477 |
) |
|
$ |
(4,608 |
) |
|
$ |
(13,809 |
) |
|
$ |
(13,813 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Cash used in operating activities |
$ |
(4,382 |
) |
|
$ |
(8,332 |
) |
|
$ |
(15,922 |
) |
|
$ |
(19,371 |
) |
Purchase of property, plant,
and equipment |
|
(972 |
) |
|
|
(6,582 |
) |
|
|
(7,622 |
) |
|
|
(23,419 |
) |
Free Cash
Flow |
$ |
(5,354 |
) |
|
$ |
(14,914 |
) |
|
$ |
(23,544 |
) |
|
$ |
(42,790 |
) |
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Lug 2023 a Lug 2024